Innovative Liquid Biopsy CIRCULOGENE specializes in advanced liquid biopsy tests that provide comprehensive genomic analysis from blood samples within a week, offering a faster and more convenient alternative to traditional tissue biopsies. This presents an opportunity to target oncology clinics and diagnostic laboratories seeking rapid, minimally invasive diagnostic solutions.

Expanding Diagnostic Portfolio The recent launch of the OncoGenDx tissue assay and LungLifeAI AI-driven blood test demonstrates CIRCULOGENE's focus on broadening its cancer diagnostics offerings. This expansion creates potential sales channels in oncology centers, pulmonology clinics, and primary care providers aiming to improve early detection and treatment decisions.

Strategic Market Expansion With offices expanded into Pensacola, Florida, and a global customer inquiry network, CIRCULOGENE is positioning itself for scalable growth in North America and later international markets, making it a promising partner for distributors and regional healthcare providers seeking innovative diagnostic technologies.

Strong Leadership & Investment Key appointments to the board, including industry veterans like Richard B. Lanman and Robert Gasparini, highlight a solid leadership backed by strategic funding and revenue growth, which can foster confidence in potential partners and clients looking for reliable and advanced diagnostic collaborations.

Growth & Market Potential With a revenue range of 25 to 50 million dollars and recent innovations in AI and tissue analysis for cancer diagnostics, CIRCULOGENE is well-positioned to capitalize on the rising demand for personalized medicine and genomic-based diagnostics, opening opportunities with biotech firms, clinics, and research institutions seeking cutting-edge solutions.